Dow announces new service featuring custom approach to drug solubilisation

Published: 1-Jan-2003


Dow Chemical has launched new services to help pharmaceutical and biopharmaceutical companies address complex challenges of dissolution-rate limited drug compounds. BioAqueous solubilisation services feature a portfolio of advanced particle engineering technologies, providing the foundation for a better solubilisation.

'Dow has established BioAqueous solubilisation services in direct response to needs identified by the pharmaceutical industry, as companies seek to introduce innovative new drugs to the market,' said Nancy Morris, Dow vice president, New Businesses.

'More than 30% of nces coming from drug discovery exhibit poor solubility characteristics. Many of these compounds show promise, if they could only be made to dissolve effectively, but as customers search for a way to enable solubilisation, it's not a case of "one size fits all".'

BioAqueous solubilisation services offer custom solutions for the particular challenges posed by individual drug compounds. Advanced particle engineering technologies, combined with the expertise of a dedicated multifunctional team, can support breakthroughs for drugs in development as well as next-generation improvements for those already on the market. 'Strategic benefits of using this new approach can include a more successful product pipeline, greater resource flexibility and faster development,' Morris said.

You may also like